These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 22287731)

  • 1. Effect of PI3K/Akt pathway inhibition-mediated G1 arrest on chemosensitization in ovarian cancer cells.
    Fekete M; Santiskulvong C; Eng C; Dorigo O
    Anticancer Res; 2012 Feb; 32(2):445-52. PubMed ID: 22287731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer.
    Choi HJ; Heo JH; Park JY; Jeong JY; Cho HJ; Park KS; Kim SH; Moon YW; Kim JS; An HJ
    Gynecol Oncol; 2019 Apr; 153(1):135-148. PubMed ID: 30686552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cisplatin and PI3kinase inhibition decrease invasion and migration of human ovarian carcinoma cells and regulate matrix-metalloproteinase expression.
    Karam AK; Santiskulvong C; Fekete M; Zabih S; Eng C; Dorigo O
    Cytoskeleton (Hoboken); 2010 Aug; 67(8):535-44. PubMed ID: 20607860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1,25-dihydroxyvitamin D(3) and PI3K/AKT inhibitors synergistically inhibit growth and induce senescence in prostate cancer cells.
    Axanova LS; Chen YQ; McCoy T; Sui G; Cramer SD
    Prostate; 2010 Nov; 70(15):1658-71. PubMed ID: 20583132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Combined inhibition of PI3K and MEK has synergistic inhibitory effect on the proliferation of cisplatin-resistant ovarian cancer cells].
    Liu Y; Chen X; Luo Z
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jun; 30(6):592-6. PubMed ID: 24909280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models.
    Hu L; Hofmann J; Lu Y; Mills GB; Jaffe RB
    Cancer Res; 2002 Feb; 62(4):1087-92. PubMed ID: 11861387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rab25 is responsible for phosphoinositide 3-kinase/AKT‑mediated cisplatin resistance in human epithelial ovarian cancer cells.
    Fan Y; Wang L; Han X; Liu X; Ma H
    Mol Med Rep; 2015 Mar; 11(3):2173-8. PubMed ID: 25405658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphatidylinositol 3-kinases inhibitor LY294002 potentiates the cytotoxic effects of doxorubicin, vincristine, and etoposide in a panel of cancer cell lines.
    Badinloo M; Esmaeili-Mahani S
    Fundam Clin Pharmacol; 2014 Aug; 28(4):414-22. PubMed ID: 23837575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potentiation of paclitaxel cytotoxicity in lung and esophageal cancer cells by pharmacologic inhibition of the phosphoinositide 3-kinase/protein kinase B (Akt)-mediated signaling pathway.
    Nguyen DM; Chen GA; Reddy R; Tsai W; Schrump WD; Cole G; Schrump DS
    J Thorac Cardiovasc Surg; 2004 Feb; 127(2):365-75. PubMed ID: 14762343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A gene signature-based approach identifies thioridazine as an inhibitor of phosphatidylinositol-3'-kinase (PI3K)/AKT pathway in ovarian cancer cells.
    Rho SB; Kim BR; Kang S
    Gynecol Oncol; 2011 Jan; 120(1):121-7. PubMed ID: 21035837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells.
    Gao N; Flynn DC; Zhang Z; Zhong XS; Walker V; Liu KJ; Shi X; Jiang BH
    Am J Physiol Cell Physiol; 2004 Aug; 287(2):C281-91. PubMed ID: 15028555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topotecan as a molecular targeting agent which blocks the Akt and VEGF cascade in platinum-resistant ovarian cancers.
    Tsunetoh S; Terai Y; Sasaki H; Tanabe A; Tanaka Y; Sekijima T; Fujioka S; Kawaguchi H; Kanemura M; Yamashita Y; Ohmichi M
    Cancer Biol Ther; 2010 Dec; 10(11):1137-46. PubMed ID: 20935474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LY294002 and metformin cooperatively enhance the inhibition of growth and the induction of apoptosis of ovarian cancer cells.
    Li C; Liu VW; Chan DW; Yao KM; Ngan HY
    Int J Gynecol Cancer; 2012 Jan; 22(1):15-22. PubMed ID: 22080879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells.
    Du J; Shi HR; Ren F; Wang JL; Wu QH; Li X; Zhang RT
    BMC Cancer; 2017 Dec; 17(1):851. PubMed ID: 29241458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of constitutively activated phosphoinositide 3-kinase/AKT pathway enhances antitumor activity of chemotherapeutic agents in breast cancer susceptibility gene 1-defective breast cancer cells.
    Yi YW; Kang HJ; Kim HJ; Hwang JS; Wang A; Bae I
    Mol Carcinog; 2013 Sep; 52(9):667-75. PubMed ID: 22488590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical testing of PI3K/AKT/mTOR signaling inhibitors in a mouse model of ovarian endometrioid adenocarcinoma.
    Wu R; Hu TC; Rehemtulla A; Fearon ER; Cho KR
    Clin Cancer Res; 2011 Dec; 17(23):7359-72. PubMed ID: 21903772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergism of PI3K/Akt inhibition and Fas activation on colon cancer cell death.
    Zhu L; Derijard B; Chakrabandhu K; Wang BS; Chen HZ; Hueber AO
    Cancer Lett; 2014 Nov; 354(2):355-64. PubMed ID: 25199763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amiloride sensitizes human pancreatic cancer cells to erlotinib in vitro through inhibition of the PI3K/AKT signaling pathway.
    Zheng YT; Yang HY; Li T; Zhao B; Shao TF; Xiang XQ; Cai WM
    Acta Pharmacol Sin; 2015 May; 36(5):614-26. PubMed ID: 25864651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effects of PI3K/Akt/NF-κB signal pathway on FSH facilitation on cell proliferation and invasion by human epithelial ovarian cancer].
    Xu CL; Lu XL; Yan XN; Wang HL; Chen SQ
    Zhonghua Fu Chan Ke Za Zhi; 2012 Feb; 47(2):134-8. PubMed ID: 22455747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequence-dependent synergism between the new generation platinum agent ZD0473 and paclitaxel in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines.
    Rogers P; Boxall FE; Allott CP; Stephens TC; Kelland LR
    Eur J Cancer; 2002 Aug; 38(12):1653-60. PubMed ID: 12142057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.